IAVI Releases Blueprint for HIV/AIDS Vaccine Research
August 6, 2008
The International AIDS Vaccine Initiative on Tuesday at the XVII International AIDS Conference released a set of guidelines aimed at developing a safe and effective HIV/AIDS vaccine, Reuters reports. According to the guidelines, researchers should concentrate on smaller, more focused vaccine trials and abandon any candidates that do not show strong promise. "Developing an AIDS vaccine may take more time and innovation than we might have once imagined, but we are confident that science will prevail," IAVI President and CEO Seth Berkley said, adding, "The necessary direction for the field is clear." According to Berkley, the cancellation of a Merck vaccine trial last year does not mean that researchers should give up on developing vaccines.
The approach outlined in the blueprint is similar to one being taken by NIH's National Institute of Allergy and Infectious Diseases to direct funding to increased laboratory work and animal tests rather than large-scale, human vaccine trials. "Strong scientific evidence in both humans and animal models suggests that developing an AIDS vaccine is possible," Wayne Koff of IAVI said.
IAVI is helping to test five vaccines with NIH, academic research institutions and companies, such as Targeted Genetics, Therion Biologics, Crucell and GlaxoSmithKline Biologicals (Fox, Reuters, 8/5).
The blueprint is available online.
Kaisernetwork.org is the official webcaster of the XVII International AIDS Conference in Mexico City. Click here to sign up for your Daily Update e-mail during the conference. A webcast of a conference session about vaccines is available online.
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.